TrialJournal of the European Academy of Dermatology and Venereology : JEADV2020

Safety and efficacy of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam in adolescent patients (aged 12 to <17 years) with plaque psoriasis: results of a phase II, open-label trial.

M Seyger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.